These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 6608980

  • 1. The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man.
    Burns RS, Markey SP, Phillips JM, Chiueh CC.
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):166-8. PubMed ID: 6608980
    [Abstract] [Full Text] [Related]

  • 2. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?
    German DC, Dubach M, Askari S, Speciale SG, Bowden DM.
    Neuroscience; 1988 Jan; 24(1):161-74. PubMed ID: 3259295
    [Abstract] [Full Text] [Related]

  • 3. Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys.
    Chiueh CC, Burns RS, Markey SP, Jacobowitz DM, Kopin IJ.
    Life Sci; 1985 Jan 21; 36(3):213-8. PubMed ID: 3871241
    [Abstract] [Full Text] [Related]

  • 4. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology.
    Imai H, Nakamura T, Endo K, Narabayashi H.
    Brain Res; 1988 Dec 06; 474(2):327-32. PubMed ID: 3264746
    [Abstract] [Full Text] [Related]

  • 5. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH.
    Nature; 1988 Dec 06; 327(6120):324-6. PubMed ID: 2884568
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?
    Herrero MT, Hirsch EC, Kastner A, Ruberg M, Luquin MR, Laguna J, Javoy-Agid F, Obeso JA, Agid Y.
    Neuroscience; 1993 Sep 06; 56(2):499-511. PubMed ID: 8247275
    [Abstract] [Full Text] [Related]

  • 9. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
    Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU.
    J Neurochem; 1992 Aug 06; 59(2):733-9. PubMed ID: 1629743
    [Abstract] [Full Text] [Related]

  • 10. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study.
    Herkenham M, Little MD, Bankiewicz K, Yang SC, Markey SP, Johannessen JN.
    Neuroscience; 1991 Aug 06; 40(1):133-58. PubMed ID: 2052148
    [Abstract] [Full Text] [Related]

  • 11. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism.
    Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA.
    Nature; 1991 Aug 06; 311(5985):464-7. PubMed ID: 6332988
    [Abstract] [Full Text] [Related]

  • 12. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.
    Schneider JS, Yuwiler A, Markham CH.
    Brain Res; 1987 May 12; 411(1):144-50. PubMed ID: 2886180
    [Abstract] [Full Text] [Related]

  • 13. MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.
    Langston JW, Langston EB, Irwin I.
    Acta Neurol Scand Suppl; 1984 May 12; 100():49-54. PubMed ID: 6333134
    [Abstract] [Full Text] [Related]

  • 14. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.
    Mochizuki H, Imai H, Endo K, Yokomizo K, Murata Y, Hattori N, Mizuno Y.
    Neurosci Lett; 1994 Feb 28; 168(1-2):251-3. PubMed ID: 8028787
    [Abstract] [Full Text] [Related]

  • 15. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
    Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR.
    Neurosci Lett; 1985 Oct 24; 61(1-2):195-200. PubMed ID: 3878482
    [Abstract] [Full Text] [Related]

  • 16. Pathology of MPTP in the marmoset.
    Gibb WR, Lees AJ, Wells FR, Barnard RO, Jenner P, Marsden CD.
    Adv Neurol; 1987 Oct 24; 45():187-90. PubMed ID: 3103386
    [No Abstract] [Full Text] [Related]

  • 17. Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas.
    Marzatico F, Café C, Taborelli M, Benzi G.
    Neurochem Res; 1993 Oct 24; 18(10):1101-6. PubMed ID: 8255359
    [Abstract] [Full Text] [Related]

  • 18. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
    Waters CM, Hunt SP, Jenner P, Marsden CD.
    Neuroscience; 1987 Dec 24; 23(3):1025-39. PubMed ID: 2893993
    [Abstract] [Full Text] [Related]

  • 19. The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset.
    Gibb WR, Lees AJ, Jenner P, Marsden CD.
    Neurosci Lett; 1986 Mar 28; 65(1):79-83. PubMed ID: 3486388
    [Abstract] [Full Text] [Related]

  • 20. Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey.
    Tanaka J, Nakamura H, Honda S, Takada K, Kato S.
    Acta Neuropathol; 1988 Mar 28; 75(4):370-6. PubMed ID: 3259063
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.